Agfa-Gevaert (AGFB) Q3 2025 earnings summary

Executive summary

• Q3 2025 revenue declined 7.1% year-over-year, mainly due to a sharp drop in medical film and the ongoing cloud transition in HealthCare IT, partially offset by growth in Digital Print & Chemicals.

• Adjusted EBITDA fell to €5 million, reflecting lower profitability in Radiology Solutions and the effects of the HealthCare IT business model shift.

• Free cash flow turned positive at €21 million in Q3, driven by a €24 million working capital improvement and a €38 million inflow from AgfaPhoto arbitration.

• Strategic focus remains on HealthCare IT's SaaS transition, growth in Digital Print & Chemicals, and accelerated restructuring in traditional film activities.

• Cost-cutting and restructuring programs have been accelerated and expanded.

Financial highlights

• Q3 2025 sales were €257 million, down from €277 million in Q3 2024 (-7.1%).

• Gross profit margin declined to 27.1% from 29.5% year-over-year.

• Adjusted EBITDA margin dropped to 2.0% from 5.5% in Q3 2024.

• Adjusted EBIT was -€4 million, compared to €4 million in Q3 2024.

• Net result for Q3 2025 was a loss of €19 million, compared to a €13 million loss in Q3 2024.

Outlook and guidance

• HealthCare IT cloud transition will continue to weigh on short-term results, with full-year profitability expected slightly below last year but order intake growth in the mid to high teens.

• Digital Print & Chemicals expected to deliver moderate top-line and slight profitability growth despite soft market conditions.

• Radiology Solutions to see continued sales and profitability decline, with restructuring to mitigate impact.

• Slightly negative net cash flow expected for FY 2025, excluding a €25 million outstanding receivable.

• Q4 anticipated to be the strongest quarter, as usual.